Stanley, A. M., Aksyuk, A. A., Wilkins, D., Green, J. A., Lan, D., Shoemaker, K., Tieu, H.-V., Sobieszczyk, M. E., Falsey, A. R., & Kelly, E. J. (2024). Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1401728

Maaske, J., Sproule, S., Falsey, A. R., Sobieszczyk, M. E., Luetkemeyer, A. F., Paulsen, G. C., Riddler, S. A., Robb, M. L., Rolle, C.-P., Sha, B. E., Tong, T., Ahani, B., Aksyuk, A. A., Bansal, H., Egan, T., Jepson, B., Padilla, M., Patel, N., Shoemaker, K., … Kelly, E. J. (2023). Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.1062067

Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., … Gonzalez-Lopez, A. (2021). Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. New England Journal of Medicine, 385(25), 2348–2360. https://doi.org/10.1056/nejmoa2105290